Back
About
The company is a clinical biotech entity developing GSK-3 inhibitor drugs to treat metastatic pancreatic cancer. Incorporated in Delaware, it focuses on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3).
Elraglusib (formerly 9-ING-41), a small molecule designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades including those mediated by oncogenes, is currently under development. This blockade of GSK-3β signaling is believed to result in the death of cancer cells and the regulation of anti-tumor immunity.
The company has exclusively licensed a portfolio of GSK-3 inhibitors developed in collaboration with the University of Illinois-Chicago (UIC) and Northwestern University (NU). The lead drug in this portfolio, elraglusib (9-ING-41), is being evaluated in a randomized Phase 2 trial in patients with metastatic pancreatic cancer, marking the most advanced clinical indication to date.
Headquarters
1751 River Run, Suite 400 Fort Worth, Texas 76107
Financial information
Underwriters
Titan Partners
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.